nespix/iStock via Getty Images Outlook Therapeutics (NASDAQ:OTLK) has made significant progress in advancing the use of its drug ONS-5010, which is being developed for the treatment of patients with wet age-related macular degeneration [Wet-AMD]. The use of this anti-VEGF drug is being explored in several studies, but the company is on the right track with…
PATRICK T. FALLON/AFP via Getty Images Investment Thesis In the rapidly evolving electric vehicle (EV) industry, I believe Rivian’s (NASDAQ:RIVN) strategic maneuvers, as outlined in its latest earnings call, articulate a firm foundation for future growth and profitability despite their near term underperformance and lower than expected production guidance for 2024. I believe a new…
Adam Berry/Getty Images Entertainment iHeartMedia, Inc. (NASDAQ:IHRT) is limping towards the end of 2023, but the company is set up for great 2024. The broadcast media company is poised to benefit from a rebound in the advertising market and the 2024 U.S. election cycle. My investment thesis remains ultra Bullish on the beaten down media…